Back to Depression And Anxiety
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00869765

NCT00869765
Completed Phase 2 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You previously took part in a specific earlier study (called HREC 07305), which tested a brain stimulation treatment for depression, and you completed that study fully.
  • At the end of that earlier study, your depression did not fully go away (measured by a standard depression score), OR your depression came back within one month of finishing that study.

Who may not be able to join:

  • You have ever been diagnosed with a psychotic disorder or obsessive compulsive disorder at any point in your life, or you currently have (or have had in the past year) an eating disorder or post-traumatic stress disorder, or you have been diagnosed with bipolar disorder or intellectual disability.
  • You have had problems with drug or alcohol misuse or dependence in the last 3 months (this does not include nicotine or caffeine).
  • Your current episode of depression did not improve after electroconvulsive therapy (a type of electric shock treatment) (confirm with trial site).
  • You regularly take a type of sedative/anxiety medication called benzodiazepines, and it would not be safe for you to stop taking them.
  • Your depression is so severe right now that you need a very fast-acting treatment, for example because of dangerously poor nutrition, psychosis, or a high risk of suicide.
  • You have a neurological condition or have had a brain injury — for example, a recent stroke — that could make brain stimulation unsafe for you.
  • You have any metal in your skull, holes or defects in your skull, or skin problems such as cuts, sores, or a rash on your scalp where the treatment electrodes would be placed.
  • You are a woman who is pregnant, or who could become pregnant and is not using reliable contraception (a urine pregnancy test will be done).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
The University of New South Wales
Registry
clinicaltrials_gov
Start date
1 April 2009
Est. completion
1 September 2010

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Inventory of Depressive Symptomatology (IDS-C)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov